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Abstract
MRE11, the nuclease component of RAD50/MRE11/NBS1 DNA repair complex which is essential for repair of DNA
double-strand-breaks in normal cells, has recently garnered attention as a critical factor in solid tumor development. Herein
we report the crucial role of MRE11 in oral cancer progression in a nuclease-independent manner and delineate its key
downstream effectors including CXCR4. MRE11 expression in oral cancer samples was positively associated with tumor
size, cancer stage and lymph node metastasis, and was predictive of poorer patient survival and radiotherapy resistance.
MRE11 promoted cell proliferation/migration/invasion in a nuclease-independent manner but enhanced radioresistance via a
nuclease-dependent pathway. The nuclease independent promotion of EMT and metastasis was mediated by RUNX2,
CXCR4, AKT, and FOXA2, while CXCR4 neutralizing antibody mitigated these effects in vitro and in vivo. Collectively,
MRE11 may serve as a crucial prognostic factor and therapeutic target in oral cancer, displaying dual nuclease dependent
and independent roles that permit separate targeting of tumor vulnerabilities in oral cancer treatment.
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Oral squamous cell carcinoma (OSCC) is the 6th most
common cancer worldwide [1], and it is particularly pre-
valent in Southeast Asian countries, with Taiwan reporting
the highest global incidence [2, 3]. Despite diagnostic and
therapeutic advances, 5-year survival globally remains
at ~50% [1].
Recently MRE11, the nuclease component of the
RAD50/MRE11/NBS1 (MRN) nuclease complex, has
attracted attention as a potential key factor in the growth,
invasion, and metastasis of a number of solid tumors
including breast, lung, ovarian, and colorectal cancer.
MRE11 is intimately involved in the DNA damage
response, preserving genomic integrity via both Homo-
logous Recombination (HR) and nonhomologous end
joining pathways [4–9]. Although MRE11 is essential for
protection of genomic stability, with nuclease activity of
MRE11 shown to facilitate protection against oncogene
induced replication stress in B lymphocytes [10], it may
likewise exhibit maladaptive effects in the protection of
established tumors from exogenous and endogenous sour-
ces of DNA damage. The clastogenic effect of ionizing
radiation (IR) and chemotherapy is impaired in high
MRE11 expressing phenotypes of breast and lung cancers,
with recent data suggesting that high MRE11 expression
lung cancer phenotypes may be protected from endogenous
tumor related replication stress [11]. Furthermore, our pre-
vious study has shown that high MRE11 expression in
breast cancer tissues was associated with more malignant
behavior in breast cancer [11], whilst conversely MRE11
deficiency was associated with better disease-free and
overall survival and improved treatment response to che-
motherapy in colorectal cancer [12]. However, there are
conflicting data regarding the role of MRE11 in carcino-
genesis, with other studies finding that MRE11 may inhibit
rather than promote oncogene driven tumorigenesis and
metastasis [13]. This may reflect its complex and incom-
pletely understood role in both protection of normal cell
phenotypes from genomic instability, and the facilitation of
cancer cell survival in the face of exogenous and endo-
genous DNA damage.
Nonetheless, the role of MRE11 in oral cancer remains to
be elucidated. In this study, we explored the role of MRE11
in oral cancer behavior in vitro and in vivo, and examined
whether MRE11 nuclease activity remains critical to oral
cancer progression. This was prompted by the observation
on cDNA microarray screening that MRE11 RNA expres-
sion was significantly elevated in oral cancer tissues com-
pared to adjacent noncancerous oral tissues in the same
patients (data not shown). Furthermore, we addressed the
possibility that elevated MRE11 expression in oral cancer
tissues may be mediated by replication stress in the tumor
microenvironment.
Results
Elevated MRE11 expression promoted malignant
oral cancer cell behavior
To evaluate whether the expression of MRE11 is dysregu-
lated in OSCC, we analyzed its expression in our OSCC
gene expression dataset and found that MRE11 mRNA is
upregulated in oral cancer tissues (T), in comparison to oral
noncancerous tissues (N) (Fig. 1A). Further analyses using
publicly available online databases showed similar results
(Fig. 1B). To assess whether MRE11 mRNA expression is
epigenetically regulated, we analyzed the correlation
between the DNA methylation level of MRE11 and its
mRNA expression level in the TCGA-HNSC dataset. A
significantly negative correlation was observed between the
MRE11 mRNA level and DNA methylation level of a CpG
site (cg26262057) at the putative promoter region of
MRE11, regardless of whether all samples (n= 520, r=
−0.16, p < 0.001) or only HPV-negative samples (n= 73,
r=−0.25, p= 0.03) were included (Fig. 1C), suggesting
that MRE11 transcription may be regulated by DNA
methylation.
To confirm whether expression of MRE11 protein was
also elevated in oral cancer tissues, immunohistochemical
analysis was performed and the results showed that MRE11
expression is relatively low in normal oral epithelium
compared to its expression level in oral cancer tissues (Fig.
1 D and E) (p= 0.0017). Further survival analyses
according to MRE11 protein expression in oral cancer tis-
sues showed that the high MRE11 expression group had
decreased overall and progression-free survivals with p
values of 0.0002 and 0.04, respectively (Fig. 1F). In
agreement with these results, an online database also con-
firmed that high MRE11 mRNA expression was associated
with decreased overall and progression-free survivals with p
values of 0.03 and 0.02, respectively (Table S1 and Fig.
1G).
The above clinical observations prompted us to study
whether MRE11 expression levels influenced oral cancer
cell behaviors. We first determined the transwell migration
activity in oral cancer cell lines. As shown in Fig. S1A,
HSC-3 and OEC-M1 cells exhibited higher migration
activity than CAL27 and CA9–22 cells. To downregulate
the expression of MRE11 in oral cancer cells, we screened 4
different lentiviral clones and clone 1 showed the highest
knockdown efficiency and was used in later knockdown
studies (Fig. S1B). We also confirmed the knockdown
efficiency of clone 1 by qRT-PCR (Fig. S1C). Using
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lentiviral knockdown and overexpression approaches, we
decreased the expression of MRE11 in HSC-3 and OEC-M1
cells which have higher endogenous MRE11 expression,
while we increased MRE11 expression in CAL 27 and
CA9–22 cells which have lower endogenous MRE11
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viability was decreased in oral cancer cells (Fig. S1E),
accompanied by decreased expression of phospho-AKT
(S473) and phospho-ERK1/2 (Fig. S1F). Knockdown of
MRE11 also led to decreased colony formation in oral
cancer cells (Fig. S1G). However, MRE11 overexpression
did not lead to increased cell viability in oral cancer cells
(Fig. S1E).
The effect of MRE11 expression on oral cancer cell
metastasis was analyzed in vitro. MRE11 knockdown
decreased, while its overexpression increased, oral cancer
cell migration as determined by wound healing assay (Fig.
2A). Further transwell migration and invasion assays also
showed similar results to the wound healing assay (Fig. 2B,
C). We further analyzed the involvement of epithelial-to-
mesenchymal transition (EMT) in MRE11-induced oral
cancer cell metastasis. Indeed, MRE11 knockdown
increased the expression of epithelial markers E-cadherin
and ZO-1, whilst decreasing expression of mesenchymal
markers vimentin, twist, and β-catenin (Fig. 2D). Con-
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epithelial markers and increased expression of mesenchy-
mal markers (Fig. 2D).
MRE11 nuclease activity is essential for
radioresistance and chemoresistance, but not cancer
cell migration, in oral cancer cells
Since MRE11 is a nuclease involved in DSB repair, it is
logical to subsequently determine whether the DSB nucle-
ase activity of MRE11 is indispensable to its metastasis-
promoting activity. Mirin is a MRE11 nuclease inhibitor
and it induced oral cancer cell death at 25 and 50 μM, but
not at 12.5 μM, when compared with untreated controls
(Fig. S1H) [14]. As depicted in Fig. 2E, mirin decreased
nuclease activity of MRE11 and led to increased γH2AX
expression upon IR exposure. However, mirin did not
inhibit proliferation or migration in oral cancer cells with
MRE11 overexpression (Fig. 2F, G). Also, the H129N
mutant of MRE11, which is defective in DSB repair, did not
inhibit the oral cancer-promoting activities of MRE11 (Fig.
2H, I).
Radiotherapy is commonly used for oral cancer treatment
due to its ability to cause significant DSBs in cancer cells.
Since MRE11 is a DNA double-strand break repair protein,
we addressed its effect on oral cancer cell viability upon IR
treatment. Knockdown of MRE11 decreased the viability of
oral cancer cells upon IR while its overexpression resulted
in the opposite effect (Figs. 3A and S2). Furthermore,
MRE11 knockdown increased DSBs while its over-
expression decreased DSBs upon IR treatment, as deter-
mined by neutral comet assay (Fig. 3B). MRE11
knockdown increased the expression of the DSB marker
γH2AX, while its overexpression decreased γH2AX
expression (Fig. 3C). Further TUNEL study for determi-
nation of apoptotic cells also demonstrated that IR led to an
increase in TUNEL-positive cells upon MRE11
Fig. 1 Elevated MRE11 expression in oral cancer tissues is asso-
ciated with decreased overall and progression-free survivals. A
Increased MRE11 mRNA expression in oral cancer tissues, in com-
parison to normal tissues, from our database. B Increased MRE11
mRNA expression in oral cancer tissues, in comparison to normal
tissues, reported in online databases. C A negative correlation between
MRE11A mRNA level and DNA methylation level in the putative
promoter region of MRE11, reported in an online database. D
Immunohistochemical staining for MRE11 protein expression in oral
noncancerous and cancer tissues. E Quantitative result for MRE11
expression in oral noncancerous and cancer tissues. F Overall survival
and progression-free survival for high and low MRE11 protein
expression groups from our dataset. G Overall survival and
progression-free survival for high and low MRE11 mRNA expression
groups reported in an online database.
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knockdown, while MRE11 overexpression led to a decrease
(Fig. 3D). For analysis of the effect of MRE11 on IR-
induced early apoptosis, Annexin V immunofluorescent
staining was performed and showed that MRE11 knock-
down increased Annexin V-positive cells while its over-
expression had the opposite effect (Fig. 3E).
In addition to IR, we also used CDDP, a chemother-
apeutic agent frequently used in oral cancer treatment for its
ability to cause DNA damage, to study the effect of MRE11
expression on CDDP-induced cancer cell death. MRE11
knockdown led to a decrease in cell viability but an
increase in comet tail formation, γH2AX expression,
Fig. 2 (Continued)
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TUNEL-positive cells, and Annexin V-positive cells, upon
CDDP treatment (Fig. S3A–E).
High MRE11 expression in oral cancer tissues was
associated with advanced cancer stage,
radioresistance, and chemoresistance
The effect of MRE11 expression, as determined by immu-
nohistochemistry, was clinically correlated with the out-
comes of radiotherapy and chemotherapy in oral cancer
patients. High MRE11 expression in oral cancer tissues was
associated with decreased overall survival following radio-
or chemotherapy, indicating a positive correlation with
radio- (Fig. 3F) and chemoresistance (Fig. S3F).
Since MRE11 expression was associated with resistance
to radio- and chemotherapy, we further analyzed the rela-
tionship between MRE11 expression and various clinical
behaviors. As shown in Table 1, high MRE11 expression in
oral cancer tissues was associated with larger tumor size,
increased lymph node metastasis, and advanced cancer
stage (Table 1). Patients with high MRE11 expression also
had a higher likelihood of receiving radiotherapy, but no
association was found with alcohol, betel nut chewing, or
cigarette smoking (Table 1). We also analyzed the con-
nection between clinicopathological characteristics of
OSCC patients and overall survival. Larger tumor size,
lymph node metastasis, radiotherapy, and high MRE11
expression in cancer tissues were risk factors for decreased
overall survival in oral cancer patients, as determined by
univariate cox regression analysis (Table 2). However in
multivariable analysis, only larger tumor size, lymph node
metastasis, and high MRE11 expression in cancer tissues
were significant risk factors (Table 2).
Fig. 2 (Continued)
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MRE11 activates RUNX2, CXCR4, and AKT, while it
inhibits FOXA2, to promote EMT and tumor growth
and metastasis in oral cancer
The clinical association of high MRE11 expression with
malignant oral cancer behaviors and reduced patient survival
prompted us to further explore its role and underlying
mechanisms in oral cancer using cell models. Using
RT [15] Profiler PCR Array—Human Tumor Metastasis
(SABioscience), which evaluates 84 genes involved in dif-
ferent tumor metastasis pathways, we compared differential
RNA expression of tumor metastasis-associated genes when
MRE11 was overexpressed (Fig. S4A). In MRE11-
overexpressing cells, RNA expression of CXCR4, a cell
membrane protein involved in cancer cell migration and
invasion [12], was increased (Fig. S4A), but this was reversed
when cells were cotreated with siCXCR4 (Fig. S4B).
RUNX2 is a transcription factor that promotes CXCR4
expression [16, 17]. Further immunoblotting analysis
showed that RUNX2 expression was upregulated when
MRE11 was overexpressed, while its expression was
downregulated when MRE11 was knockdowned (Fig. 4A).
Fig. 2 (Continued)
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Immunohistochemistry analysis also showed a positive
correlation between the expression of MRE11 and RUNX2
in oral cancer tissues (Fig. 4B).
A positive correlation between the expression of RUNX2
and CXCR4, as determined by immunohistochemistry ana-
lysis, was observed in oral cancer tissues (Fig. 4C). Further
western blotting analysis confirmed that CXCR4 expression
in oral cancer cells was decreased when MRE11 was
knockdowned (Fig. 4D). We then checked the association
between MRE11 and CXCR4 by immunohistochemistry
using oral cancer tissue specimens. As shown in Fig. 4E,
MRE11 and CXCR4 were positively correlated in primary
oral cancer tissues and CXCR4 was more highly expressed in
oral cancer tissues with lymph node metastasis.
Previous studies have reported that CXCR4 signaling is
involved in the establishment of lymph node metastasis in
oral cancer through AKT activation [18]. In this study, S473
phosphorylation of AKT was decreased upon MRE11
knockdown but was increased upon MRE11 overexpression
in oral cancer cells (Fig. 4F). Further study using clinical
oral cancer specimens confirmed a positive correlation
between the expression of MRE11 and S473 phospho-AKT
(Fig. 4G). To determine whether AKT activation is indeed
the downstream effector of MRE11, MRE11-overexpressed
Fig. 2 Metastasis-promoting activity of MRE11 in oral cancer cells
is independent of its nuclease activity. A MRE11 knockdown
decreased, while its overexpression increased, wound closure in oral
cancer cells. B MRE11 knockdown decreased, while its over-
expression increased, transwell migration in oral cancer cells. C
MRE11 knockdown decreased, while its overexpression increased,
transwell invasion in oral cancer cells. D MRE11 knockdown
decreased, while its overexpression increased, epithelial-to-
mesenchymal transition in oral cancer cells. E Mirin, a MRE11
nuclease inhibitor, increased the expression of γH2AX, an indicator of
DSB, in oral cancer cells upon ionizing radiation exposure. F Mirin
treatment did not inhibit the proliferation-promoting activity of
MRE11 in oral cancer cells. G Mirin treatment did not inhibit the
migration-promoting activity of MRE11 in oral cancer cells. H
Nuclease-deficient MRE11 with H129N mutation showed
proliferation-promoting activity. I Nuclease-deficient MRE11 with
H129N mutation showed migration-promoting activity.
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cells were treated with wortmannin, a PI3K/AKT inhibitor,
and the result showed that MRE11-induced cancer cell
migration was indeed blocked by cotreatment with
wortmannin (Fig. 4H). CXCR4 knockdown also reversed
AKT phosphorylation in oral cancer cells induced by
MRE11 overexpression (Fig. 4I). In addition, AKT
phosphorylation induced by SDF, a CXCR4 ligand, in
MRE11-overexpressing cells was reversed by cotreatment
with CXCR4 mAb (Fig. 4J).
Transcription factor FOXA2, a member of the forkhead
box protein 2A/winged-helix family, binds to the promoter
of CDH1 and upregulates the expression of E-cadherin, the
gene product of CDH1 [19]. A previous study has
demonstrated that FOXA2 is hypermethylated in various
Fig. 3 (Continued)
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cancer cell lines [20]. To explore the underlying mechan-
isms of MRE11-induced oral cancer cell metastasis, the
expression of FOXA2 was analyzed. MRE11 knockdown in
oral cancer cells led to increased expression of FOXA2,
which was blocked by cotreatment with SC79, an AKT
activator (Fig. 4K). FOXA2 is a transcriptional factor
which, when activated, moves to the nucleus to activate the
transcription of downstream effectors including E-cadherin
[21]. While FOXA2 stayed in the cytosol when MRE11 was
overexpressed, it moved to the nucleus when MRE11-
overexpressing cells were cotreated with wortmannin (Fig.
4L). However in MRE11-knockdowned cells, FOXA2
moved to the nucleus (Fig. S5A). We also observed a
negative correlation between the expression of MRE11 and
FOXA2 in both oral cancer tissues and metastatic lymph
nodes (Fig. 4M), and a negative correlation between the
expression of S473 phospho-AKT and FOXA2 (Fig. 4N). A
negative correlation between MRE11 and E-cadherin
expression and a positive correlation between FOXA2 and
E-cadherin (a downstream effector of FOXA2) expression
were also observed in oral cancer tissues (Fig. S5B, C).
Furthermore, a positive correlation between MRE11 and
CXCR4 expression and a negative correlation between both
MRE11/FOXA2 expression and CXCR4/FOXA2 expres-
sion were observed from heat map view and scatter/corre-
lation plot using oral cancer microarray datasets from
ONCOMINE Cancer Profiling Database (https://www.
oncomine.org) (Fig. S5D).
MRE11-promotion of tumor growth and metastasis
was suppressed by inhibition of CXCR4 activity
Finally, the effect of MRE11 on oral cancer behaviors was
addressed with animal models. An orthotopic HSC3 oral
cancer model was developed in SCID mice by injecting
cancer cells into the buccal area of mice. Smaller tumor
volume was observed in MRE11 knockdown group
(shMRE11) compared to control group (shLuc) (Fig. 5A).
Tumor lesions were evaluated weekly with IVIS analysis,
and a significantly lower luciferase activity determined by
total flux was observed at 7th and 8th weeks in MRE11
knockdown group (shMRE11) compared to control group
(shLuc) (Fig. 5B). The luciferase activity was significantly
lower in MRE11 knockdown group at sacrifice (Fig. 5C).
Fig. 3 High MRE11 expression in oral cancer cells leads to che-
moresistance, radioresistance, and decreased patient survival. A
The effect of MRE11 knockdown and overexpression on colony for-
mation in oral cancer cells after ionizing radiation exposure. B The
effect of MRE11 knockdown and overexpression on comet tail for-
mation, an indicator for DSBs, in oral cancer cells after ionizing
radiation treatment. C The effect of MRE11 knockdown and over-
expression on γH2AX expression, an indicator for DSBs, in oral
cancer cells after ionizing radiation exposure. D The effect of MRE11
knockdown and overexpression on oral cancer cell apoptosis, deter-
mined by TUNEL positivity, after ionizing radiation treatment. E The
effect of MRE11 knockdown and overexpression on oral cancer cell
apoptosis, determined by Annexin V positivity, after ionizing radiation
treatment. F The effect of MRE11 expression, determined by IHC, on
overall survival of oral cancer patients after radiotherapy.
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The oral tumors were collected for immunohistochemistry
analysis for the expression of MRE11, Ki67, RUNX2,
CXCR4, phospho-AKT, and FOXA2. In agreement with
the in vitro and clinical data, knockdown of MRE11 led to
decreased expression of Ki67, CXCR4, and phospho-AKT,
but increased expression of FOXA2 (Fig. 5D–I). We also
analyzed cervical lymph node (CLN) metastasis in the
orthotopic mouse model by using LN1-1 oral cancer cells, a
subline of OEC-M1 isolated from metastatic CLNs. Figure
5J shows an example of CLN metastasis demonstrated by
IVIS imaging and Fig. 5K shows H&E stains. The quanti-
tative data of CLN metastasis showed decreased NLN
Table 1 The association of
MRE-11 expression and
clinicopathological
characteristics of OSCC patients
using logistic regression.





N (%) N (%)
Histopathological grade I 72 (44.2) 91 (55.8) 0.86 1 1




Tumor size T1 45 (54.9) 37 (45.1) 0.0071 1 1




Lymph node metastasis No 71 (52.2) 65 (47.8) <0.0001 1 1




Pathologic stage I+ II 59 (56.2) 46 (43.8) <0.0001 1 1




Radiotherapy No 62 (53.0) 55 (47.0) 0.0008 1 1




Sex Female 7 (63.6) 4 (36.4) 0.18 1 1




Alcohol drinking No 21 (45.7) 25 (54.3) 0.63 1 1




Betel quid chewing No 17 (43.6) 22 (56.4) 0.86 1 1




Cigarette smoking No 18 (52.9) 16 (47.1) 0.14 1 1




Table 2 Association between
clinicopathological
characteristics of OSCC patients
and overall survival.
Variable N Univariate p value Multivariable p value
HR (95% CI) HR (95% CI)
Histopathological grade I 163 1 – –
II+ III+ IV 19 1.11 (0.38–2.61) 0.83 – –
Tumor size T1(<2 cm) 82 1 0.0006 1 0.02
T2–T4 100 3.21 (1.62–6.82) 2.26 (1.12–4.86)
Lymph node metastasis No 136 1 <0.0001 1 0.004
Yes 46 3.78 (1.99–7.20) 2.71 (1.39–5.29)
MRE11 Low 80 1 0.0002 1 0.01
High 102 4.23 (1.90–11.234) 2.94 (1.26–8.03)
Radiotherapy No 117 1 0.03 1 0.65
Yes 65 2.61 (1.07–3.81) 1.17 (0.60–2.31)
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Fig. 4 (Continued)
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metastasis in mice injected with oral cancer cells with
MRE11 knockdown. Of note, MRE11 knockdown in LN1-
1 cells decreased cell viability at 72 h (Fig. S6A) and
decreased transwell migration at 24 h after incubation (Fig.
S6B). In orthotopic mouse model, MRE11 knockdown in
LN1-1 cells led to decreased total flux (Fig. S6C) and
reduced tumor volume (Fig. S6D) of orthotopic oral tumors.
We also noticed decreased expression of mesenchymal
marker vimentin and increased expression of epithelial
marker E-cadherin in the above mentioned orthotopic tumor
model (Fig. S7A, B).
To study the effect of MRE11 expression on cancer cell
metastasis in vivo, we injected the oral cancer cells into the
perivitelline space of 2 days old zebrafish embryos.
Fig. 4 (Continued)
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Fig. 4 CXCR4, RUNX2, AKT, and FOXA2 are involved in MRE11-induced oral cancer metastasis. A MRE11 knockdown led to decreased
RUNX2 expression, while MRE11 overexpression led to increased RUNX2 expression, in oral cancer cells. B The correlation of RUNX2
expression in oral cancer tissues with MRE11 expression and lymph node metastasis in oral cancer patients. C A positive correlation between
RUNX2 and CXCR4 expression in oral cancer tissues. D CXCR4 expression in oral cancer cells was decreased when MRE11 was knockdowned.
EMRE11 and CXCR4 were positively correlated in primary oral cancer tissues and CXCR4 was more highly expressed in oral cancer tissues with
lymph node metastasis. F MRE11 knockdown led to decreased pAKT expression, while MRE11 overexpression led to increased pAKT
expression, in oral cancer cells. G The correlation between MRE11 and pAKT expression in oral cancer tissues. H Wortmannin, a PI3K/AKT
inhibitor, reversed the increased oral cancer migration induced by MRE11 overexpression. I CXCR4 silencing reversed the increased pAKT
expression caused by MRE11 overexpression. J CXCR4 blocking mAb reversed the increased pAKT expression caused by SDF-1, a CXCR4
activator, in MRE11-overexpressing oral cancer cells. K MRE11 knockdown in oral cancer cells led to increased expression of nuclear FOXA2,
which was partially reversed by cotreatment with AKT activator SC79. L MRE11 overexpression in oral cancer cells decreased the nuclear
expression of FOXA2 while treatment with wortmannin reversed the increased nuclear expression of FOXA2 induced by MRE11 overexpression.
M Correlation of MRE11 and FOXA2 expression in oral cancer tissues and metastatic lymph nodes. N Correlation of phospho-AKT and FOXA2
expression in oral cancer tissues and metastatic lymph nodes.
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MRE11-knockdowned oral cancer cells showed decreased
migration into GFP-stained blood vessels, and MRE11-
overexpressed oral cancer cells showed increased migration
(Fig. 6A, B and Table S2). Using SCID mice tail vein
injection model, we observed increased lung metastasis,
evidenced by increased luminescence and tumor nodule
formation, in mice injected with MRE11-overexpressing
oral cancer cells (Fig. 6C, D). Furthermore, decreased
FOXA2 expression and elevated expression of MRE11,
Ki67, CXCR4, and S473-phospho-AKT were observed in
MRE11-overexpressing lung tumor nodules (Fig. 6E–H).
To explore potential treatment strategies for MRE11-
overexpressing oral cancers in vivo, we tested the efficacy
of targeting CXCR4 with neutralizing antibody in mice
(Fig. 6I). Neutralizing CXCR4 antibody mitigated lung
metastasis promotion by MRE11 overexpression, as
evidenced by decreased luminescence and tumor nodule
formation.
Fig. 5 (Continued)
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Fig. 5 MRE11 knockdown decreased orthotopic oral tumor
growth and cervical lymph node (CLN) metastasis with decreased
expression of CXCR4 and pAKT but increased expression of
FOXA2 in oral cancer tissues. A The effect of MRE11 knockdown in
oral cancer cells on orthotopic oral tumor volume. B The effect of
MRE11 knockdown in oral cancer cells on weekly total flux of
orthotopic oral tumors. C The effect of MRE11 knockdown in oral
cancer cells on total flux of orthotopic oral tumors at sacrifice. D–I The
effect of MRE11 knockdown in oral cancer cells on the expression of
MRE11, Ki67, RUNX2, CXCR4, pAKT, and FOXA2 in oral tumor
tissues. J An example of CLN metastasis shown by IVIS imaging and
H&E stain. K Quantitative data of CLN metastasis in mice when
MRE11 expression in oral cancer cells was knockdowned.
Y.-Y. Wang et al.
Discussion
This is the first study to highlight the significance of MRE11 in
oral cancer progression, and adds to the growing body of
literature indicating the importance of the chemokine receptor
CXCR4 in a multitude of cancers. We have shown that in
addition to its well recognized nuclease activity, MRE11 pro-
motes EMT and cancer stemness through nuclease independent
activation of RUNX2, CXCR4, and AKT to inhibit FOXA2/E-
cadherin, leading to cancer growth and metastasis, radio- and
chemoresistance, and poor survival in oral cancer patients (Fig.
6J). This pathway provides a range of potential downstream
therapeutic targets—in particular chemokine receptor CXCR4
—for which real-time clinical assessment with CXCR4 direc-
ted PET imaging has recently been developed [22].
Differential MRE11 nuclease and non-nuclease
dependent effects in oral cancer
Although elevated MRE11 expression was associated with
a more malignant cancer phenotype, disparate MRE11
nuclease and non-nuclease activities were found to mediate
distinct aspects of the cancer phenotype. MRE11 nuclease
dependent activity appears to be pivotal in clastogenic
resistance to chemo and radiotherapy, with specific MRE11
nuclease inhibitor (Mirin) and MRE11 nuclease-deficient
mutant (H129N) resulting in increased sensitivity to clas-
togenic therapies. Consequently it appears that MRE11
nuclease activity, although protective of genomic integrity
in the normal cell phenotype, may be maladaptive in the
cancer phenotype by permitting tumor cell viability in the
face of exogenous DNA damage from clastogenic therapies
and endogenous DNA replication stress. Strikingly, inhibi-
tion of MRE11 nuclease activity had no effect on tumor
proliferation and metastasis, with our data indicating that
MRE11 may separately mediate these effects via a nuclease
independent pathway involving RUNX2—a transcription
factor which promotes CXCR4 expression, AKT activation,
and subsequent inhibition of FOXA2/E-Cadherin activity.
Although these nuclease dependent and independent activ-
ities appear to be responsible for disparate cancer behaviors,
mutual regulation may exist between these pathways with
RUNX2 deficiency previously shown to result in loss of
MRE11/RAD50/NBS1 DNA repair complex, indicating
that RUNX2 may be an upstream regulator of MRE11
nuclease activity [23]. Furthermore, AKT may inhibit
DSB repair in colon cancer cells via inhibition of MRE11
by p70S6 kinase [24], suggesting the presence of a
feedback loop between MRE11 and AKT [25]. This
feedback loop is not alone and has also been reported in
other couples, e.g., ZEB/miR-200, MDM2/p53, PI3K/
mTOR, and E2F1-C/EBPα [15, 26–29]. Mutual regulation
of MRE11 is therefore multifactorial and incompletely
elucidated, and may involve RUNX2 and AKT in a cell
type-dependent manner.
The nuclease-independent role of MRE11 in promotion
of EMT and metastasis in oral cancer cells was also tested
and confirmed in lung cancer cells (data not shown).
Whether this mechanism is unique to oral and lung cancer
cells that we tested or is universal to various cancer cell
types merits further investigation.
MRE11 and CXCR4 signaling is not conserved across
different cell types
The MRE11 signaling pathway is not conserved across
different cell types, with our prior report indicating that
MRE11 mediates its effects in breast cancer via STAT3 and
its downstream effectors cyclin D, Myc, and BCL-xL [11].
In the current study, we did not observe similar involvement
of STAT3 in oral cancer (Fig. S8), suggesting that cell type
differences between oral cancer (squamous cell carcinoma)
and breast cancer (adenocarcinoma) may contribute to
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Likewise, the chemokine receptor CXCR4 has multiple
upstream mediators, with upregulation in renal cell carci-
noma described in response to hypoxia inducible factor
(HIF1a) [30] and galectin 1 [31], and in breast cancer with
angiotensin II type I receptor (AGTR-1) and NF kappa B
[32, 33].
Future clinical applications targeting CXCR4 for
treatment of MRE11-overexpressing oral cancer
Our findings suggest that MRE11 inhibition may pose an
attractive therapeutic target in oral squamous cell cancer,
but potential problems exist in balancing the complexity of
altering a potentially beneficial (preservation of genome
integrity in the normal phenotype) and potentially mala-
daptive response (abrogation of the DDR to clastogenic
therapies and endogenous tumor replication stress), together
with the current paucity of suitable clinical antagonists, real-
time functional DDR assays and noninvasive methods of
MRE11 quantification. Nonetheless, DDR inhibitors pre-
sent the next generation of anticancer therapeutic strategies,
with the PARP inhibitors in BRCA-mutant ovarian and
breast cancers the paradigm in this field [34]. In this
regard, tumors expressing phosphomimetic (inactive)
MRE11 are more sensitive to the PARP inhibitor olaparib,
compared with those expressing unphosphorylatable
Fig. 6 (Continued)
Y.-Y. Wang et al.
MRE11, suggesting that patients with elevated Plk1
expression may benefit from olaparib treatment [35].
CXCR4 may currently provide a more mature therapeutic
target than MRE11. CXCR4 has been shown in this study to
be critical to OSCC invasion and metastasis, and has gar-


































































Fig. 6 MRE11 expression in oral cancer cells is associated with
metastasis in zebrafish and mouse models. A An example of oral
cancer cell migration in zebrafish. B Quantitation of the effects of
MRE11 knockdown and overexpression in oral cancer cells on
migration in zebrafish model. C The effect of MRE11 overexpression
in oral cancer cells on total flux of lung metastasis. D The effect of
MRE11 overexpression in oral cancer cells on metastatic lung tumor
area. E–H The effect of MRE11 overexpression in oral cancer cells on
the expression of MRE11, RUNX2, CXCR4, and pAKT in metastatic
lung tumor tissues. I CXCR4 neutralizing antibody reverse the cancer
metastasis promoted by MRE11 overexpression in mouse model.
Representative microscopic views of the lung sections. Hematoxylin-
positive blue-colored nodules indicate metastatic colony number
(Student’s t test) and tumor area (%) (Mann–Whitney U test). J
Schematic diagram for MRE11 signaling pathway and activity.
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tumor types, with overexpression in at least 23 other cancer
types [36]. The development of specific antagonists such as
balixafortide, which has recently completed Phase I clinical
trials in HER2 negative metastatic breast cancer, shows
promise [37]. Together with 68Ga-pentixafor/PET imaging,
this may allow the noninvasive real-time assessment of
CXCR4 specific therapies in the future [22].
Upstream regulators for MRE11 and the role of
replication stress
Upstream regulation and overexpression of MRE11 in oral
cancer remains one of the key issues to be resolved. Whilst
this study focused on the downstream events of MRE11 in
oral cancer, we have shown that MRE11 overexpression is
not simply reactive to replication stress, but is likely to be
a complex and multifactorial process comprising epige-
netic regulation, mutual regulation, and other upstream
regulators. Cancer cells are constantly exposed to repli-
cation stress and replication-associated DDR, which may
in turn activate MRE11 expression [10, 38], but we found
no association between MRE11 expression and the
expression of phosphorylated ATM, phosphorylated ATR,
and γ-H2AX in oral cancer tissues (Fig. S9). Instead, our
results point towards epigenetic regulation playing a more
prominent role in MRE11 overexpression, with data
showing a significant negative correlation with DNA
methylation at the putative promoter region (CpG site
cg26262057), regardless of HPV status. The upstream
regulation of MRE11 may also involve mutual regulation
by AKT/MRE11 and RUNX2/MRE11 as discussed pre-
viously, with other proposed factors including ribosomal
s6 kinase (Rsk), Polo-like kinase 1 (Plk1), and FGFR2.
Rsk and Plk1 both suppress DNA-damage checkpoint
signaling by phosphorylating and inhibiting MRE11
activity [35, 39], whilst FGFR2 regulates MRE11
expression through the MEK/ERK/POU1F1 pathway in
breast cancer [40].
Conclusions
In this study, we conclude that MRE11 may serve as a
crucial prognostic factor and therapeutic target in oral
cancer, displaying dual nuclease dependent and indepen-
dent roles that permit separate targeting of tumor vul-
nerabilities to the DNA damage response and EMT,
migration and metastasis. CXCR4, a downstream effector
of RUNX2 transcription factor, presents an exciting
and viable target in oral cancer, with both antagonists and
CXCR4 directed imaging in the mature stage of
development.
Materials and methods
Details of all methods are found in Supplementary
Information.
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